# US 2008/0188506 A1 · Spiroindolinone derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188506 A1
- Document ID: US20080188506A1
- Status: Published application
- Kind: A1
- Application number: 12/023,142
- Filed: 2008-01-31
- Published: 2008-08-07
- Earliest claimed: 2007-02-07
- Inventors: Qingjie Ding; Jin-Jun Liu; Zhuming Zhang
- Web page: https://patentgrep.com/patent/US20080188506A1

## CPC

- C07D 471/10: Spiro-condensed systems
- C07D 471/20: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

There are provided spiroindolinones of the formula and enantiomers and pharmaceutically acceptable salts and esters thereof which have utility as antiproliferative agents, especially, as anticancer agents.

## Claims

### Claim 1

A compound selected from the group consisting of
wherein
X is selected from the group consisting of hydrogen, halogen, cyano, nitro, ethynyl, cyclopropyl, methyl, ethyl, isopropyl, methoxy, and vinyl,
Y is hydrogen or fluorine,
R4, R5 are selected from the group consisting of hydrogen and lower alkyl, one of R1 and R8 is selected from the group consisting of lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl and the other is hydrogen,
one of R6 and R7 is selected from the group consisting of lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl and the other is hydrogen, lower alkyl or cyano
R2 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, C(═O)R9, C(═O)NHR9, C(═O)NR9R9′ and C(═O)OR9,
R3 is selected from the group consisting of NHR9, SR9, and NR9R9,
R9 is selected from the group consisting of lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl and substituted cycloalkyl,
R9′ is selected from the group consisting of lower alkyl and substituted lower alkyl
and in the case of R9 and R9′ they may independently link to form a cyclic structure selected from heterocycle or substituted heterocycle and
R10 is selected from the group consisting of hydrogen, hydroxyl and lower alkyl and the pharmaceutically acceptable salts and esters thereof.

### Claim 2

A compound of the formula
wherein
X is Cl or Br,
Y is hydrogen,
R1 is hydrogen,
R4 and R5 are both hydrogen,
R6 is hydrogen,
R7 is a substituted phenyl or substituted heteroaryl selected from group consisting of
R8 is selected from the group consisting of lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl,
R3 is selected from the group consisting of NHR9 and NR9R9′,
R9 is selected from the group consisting of lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl and substituted cycloalkyl,
R9′ is selected from the group consisting of lower alkyl and substituted lower alkyl
and in the case of R9 and R9′ they may independently link to form a cyclic structure selected from heterocycle or substituted heterocycle and the pharmaceutically acceptable salts and esters thereof.

### Claim 3

A compound of the formula
Wherein
X is Cl or Br,
Y is hydrogen,
R1 is hydrogen,
R4 and R5 are both hydrogen,
R6 is hydrogen,
R7 is a substituted phenyl or substituted heteroaryl selected from group consisting of
R8 is selected from the group consisting of lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl,
R10 is selected from the group consisting of hydrogen, hydroxyl, and methyl and the pharmaceutically acceptable salts and esters thereof.

### Claim 4

A compound of the formula
wherein
X is Cl or Br
Y is hydrogen,
R1 is hydrogen,
R4 and R5 are both hydrogen,
R6 is hydrogen,
R7 is a substituted phenyl or substituted heteroaryl selected from group consisting of
R8 is selected from the group consisting of lower alkyl, substituted alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl,
R2 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, C(═O)R9, C(═O)NHR9, C(═O)NR9R9′ and C(═O)OR9,
R9 is selected from the group consisting of lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, cycloalkyl and substituted cycloalkyl,
R9′ is selected from the group consisting of lower alkyl and substituted lower alkyl
and in the case of R9 and R9′ they may independently link to form a cyclic structure selected from heterocycle and substituted heterocycle and the pharmaceutically acceptable salts and esters thereof.

### Claim 5

A compound of the formula
Wherein
X is Cl or Br,
Y is hydrogen,
R1 is hydrogen,
R4 and R5 are both hydrogen,
R6 is hydrogen,
R8 is a substituted phenyl selected from group consisting of
R7 is selected from the group consisting of lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl.
R2 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, C(═O)R9, C(═O)NHR9, C(═O)NR9R9′ and C(═O)OR9,
R9 is selected from the group consisting of lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, cycloalkyl and substituted cycloalkyl,
R9′ is selected from the group consisting of lower alkyl and substituted lower alkyl
and in the case of R9 and R9′ they may independently link to form a cyclic structure selected from heterocycle and substituted heterocycle and the pharmaceutically acceptable salts and esters thereof.

### Claim 6 (depends on 1)

A compound of claim 1 selected from the group consisting of racemic (2′S, 3S, 4′S)-6-chloro-2′-(3-chlorophenyl)-4′-(2,2-dimethylpropyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′S, 3R)-6-chloro-2′-(3-chlorophenyl)-2′,3′,4′,5′-tetrahydro-4′-isopropyl-6′-(methylthio) spiro[3H-indole-3,3′-pyridin]-2(1H)-one,
racemic (2′S, 3S, 4′S)-6-chloro-2′-(3-chlorophenyl)-4′-ethyl spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(3-methylphenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(3-fluorophenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′S, 3S, 4′R)-6-chloro-2′-(3-chlorophenyl)-4′-phenyl spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S, 5′S)-6-chloro-4′-(3-chlorophenyl)-5′-methyl-2′-(2-methylphenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(3-methoxyphenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(3-cyanophenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one and
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(2,3-dimethylphenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one.

### Claim 7 (depends on 1)

A compound of claim 1 selected from the group consisting of
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-[2-(trifluoromethyl)-phenyl)]spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′S, 3R)-6-chloro-4′-(3-chlorophenyl)-2′,3′,4′,5′-tetrahydro-6′-(methylthio)-2′-[2-(trifluoromethyl)-phenyl]spiro[3H-indole-3,3′-pyridin]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-[5-fluoro-2-(trifluoromethyl)-phenyl]spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(5-fluoro-2-methylphenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(2,4-difluorophenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(5-fluoro-2-methoxyphenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(1-naphthalenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(3-pyridinyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(3,4-difluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one and
racemic (5′R, 3R, 7′S)-6-chloro-7′-(3-chlorophenyl)-5′-(3,4-difluorophenyl)-5′,6′,7′,8′-tetrahydro-3′-hydroxyspiro[3H-indole-3,6′-(1,2,4-triazolo[4,3-a]pyridine)]-2(1H)- one.

### Claim 8 (depends on 1)

A compound of claim 1 selected from the group consisting of
racemic (5′R, 3R, 7′S)-6-chloro-7′-(3-chlorophenyl)-5′-(5-fluoro-2-methylphenyl)-5′,6′,7′,8′-tetrahydro-3′-hydroxyspiro[3H-indole-3,6′-(1,2,4-triazolo[4,3-a]pyridine)]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(2,3-difluoro-6-methylphenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4S)-6-chloro-4′-(3-chlorophenyl)-5-fluoro-2′-(5-fluoro-2-methylphenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(1-ethyl-propyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chloro-phenyl)-2′-(2,5-dimethyl-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(2,5-dimethyl-2H-pyrazole-3-yl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chlorophenyl)-1′-(morpholin-4-carbonyl)-2′-(1-naphthalenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′S, 3S, 4′R)-6-chloro-4′-(4-chloro-phenyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′S, 3S, 4′R)-1′-tert-butylaminocarbonyl-6-chloro-4′-(4-chloro-phenyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one and
racemic (2′S, 3S, 4′R)-6-chloro-4′-(4-chloro-phenyl)-1′-(3-cyano-phenylaminocarbonyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one.

### Claim 9 (depends on 1)

A compound of claim 1 selected from the group consisting of
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chloro-phenyl)-1′-(3-cyano-phenylaminocarbonyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-1′-tert-butylaminocarbonyl-6-chloro-4′-(3-chloro-phenyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-1′-benzoyl-6-chloro-4′-(3-chloro-phenyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-1′-acetyl-6-chloro-4′-(3-chloro-phenyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-1′-[4-(amonocarbonylmethyl)-piperazine-1-carbonyl]-6-chloro-4′-(3-chloro-phenyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chloro-phenyl)-2′-(3-fluoro-phenyl)-1′-[4-(3-methanesulfonyl-propyl)-piperazine-1-carbonyl]spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chloro-phenyl)-2′-(3-fluoro-phenyl)-1′-[4-(2-oxo-2-pyrrolidin-1-yl-ethyl)-piperazine-1-carbonyl]spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-1′-[4-(2-acetylamino-ethyl)-piperazine-1-carbonyl]-6-chloro-4′-(3-chloro-phenyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one and
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chloro-phenyl)-2′-(3-fluoro-phenyl)-1′-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]spiro[3H-indole-3,3′-piperidine]-2(1H)-one.

### Claim 10 (depends on 1)

A compound of claim 1 selected from the group consisting of
racemic (2′R, 3R, 4′S)-6-chloro-4′-(3-chloro-phenyl)-1′-cyclohexylaminocarbonyl-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (2′R, 3R, 4′S)-1′-benzylaminocarbonyl-6-chloro-4′-(3-chloro-phenyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (5′R, 3R, 7′S)-6-chloro-7′-(3-chlorophenyl)-5′-(2,3-difluoro-6-isopropoxy-phenyl)-5′,6′,7′,8′-tetrahydro-3′-hydroxyspiro[3H-indole-3,6′-(1,2,4-triazolo[4,3-a]pyridine)]-2(1H)-one,
chiral (5′R, 3R, 7′S)-6-chloro-7′-(3-chlorophenyl)-5′-(2,3-difluoro-6-isopropoxy-phenyl)-5′,6′,7′,8′-tetrahydro-3′-hydroxyspiro[3H-indole-3,6′-(1,2,4-triazolo[4,3-a]pyridine)]-2(1H)-one,
racemic (2′R, 3R, 4′S)-1′-hydroxycarbonylmethyl-6-chloro-4′-(3-chloro-phenyl)-2′-(3-fluoro-phenyl) spiro[3H-indole-3,3′-piperidine]-2(1H)-one,
racemic (5′R, 3R, 7′S)-6-chloro-7′-(3-chlorophenyl)-5′-(1-methylene-butyl)-5′,6′,7′,8′-tetrahydro-spiro[3H-indole-3,6′-(1,2,4-triazolo[4,3-a]pyridine)]-2(1H)-one,
chiral (5′R, 3R, 7′S)-6-chloro-7′-(3-chlorophenyl)-5′-(1-methylene-butyl)-5′,6′,7′,8′-tetrahydro-spiro[3H-indole-3,6′-(1,2,4-triazolo[4,3-a]pyridine)]-2(1H)-one,
racemic (5′R, 3R, 7′S)-6-chloro-7′-(3-chlorophenyl)-3′-methyl-5′-(1-methylene-butyl)-5′,6′,7′,8′-tetrahydro-spiro[3H-indole-3,6′-(1,2,4-triazolo[4,3-a]pyridine)]-2(1H)-one,
racemic (2′R, 3′R,4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(5-fluoro-2-methyl-phenyl)-6′-(1,4-piperazinyl)-spiro[3H-indole-3,3′-2′,3′,4′,5′-tetrahydro-pyridine]-2-one and
racemic (2′R, 3′R,4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(5-fluoro-2-methyl-phenyl)-6′-[4-[1,1-dimethylethoxy-carbonyl]amino]ethylamino-spiro[3H-indole-3,3′-2′,3′,4′,5′-tetrahydro-pyridine]-2-one.

### Claim 11 (depends on 1)

A compound of claim 1 selected from the group consisting of
racemic (2′R, 3′R,4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(5-fluoro-2-methyl-phenyl)-6′-[4-amino]ethylamino-spiro[3H-indole-3,3′-2′,3′,4′,5′-tetrahydro-pyridine]-2-one, trifluoroacetic acid,
racemic (2′R, 3′R,4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(5-fluoro-2-methyl-phenyl)-6′-(4-methyl-1-piperazinyl)-spiro[3H-indole-3,3′-2′,3′,4′,5′-tetrahydro-pyridine]-2-one,
racemic (2′R, 3′R,4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(5-fluoro-2-methyl-phenyl)-6′-[[tetrahydro-1,1-dioxido-2H-thiopyran-4-yl]piperazinyl-spiro[3H-indole-3,3′-2′,3′,4′,5′-tetrahydro-pyridine]-2-one,
racemic (2′R, 3′R,4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(5-fluoro-2-methyl-phenyl)-6′-[4-(3-methylsulphonyl)-propyl]piperazinyl-spiro[3H-indole-3,3′-2′,3′,4′,5′-tetrahydro-pyridine]-2-one and
racemic (2′R, 3′R,4′S)-6-chloro-4′-(3-chlorophenyl)-2′-(5-fluoro-2-methyl-phenyl)-6′-[1-methylsulphonyl-4-piperidinyl]amino-spiro[3H-indole-3,3′-2′,3′,4′,5′-tetrahydro-pyridine]-2-one.

### Claim 12

A pharmaceutical formulation comprising a compound of the formula
wherein
X is selected from the group consisting of hydrogen, halogen, cyano, nitro, ethynyl, cyclopropyl, methyl, ethyl, isopropyl, methoxy, and vinyl,
Y is hydrogen or fluorine,
R4, R5 are selected from the group consisting of hydrogen and lower alkyl one of R1 and R8 is selected from the group consisting of lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl and the other is hydrogen,
one of R6 and R7 is selected from the group consisting of lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl and the other is hydrogen, lower alkyl or cyano
R2 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, C(═O)R9, C(═O)NHR9, C(═O)NR9R9′ and C(═O)OR9,
R3 is selected from the group consisting of NHR9, SR9, and NR9R9′,
R9 is selected from the group consisting of lower alkyl, substituted lower alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl and substituted cycloalkyl,
R9′ is selected from the group consisting of lower alkyl and substituted lower alkyl
and in the case of R9 and R9′ they may independently link to form a cyclic structure selected from heterocycle or substituted heterocycle,
R10 is selected from the group consisting of hydrogen, hydroxyl and lower alkyl and the pharmaceutically acceptable salts and esters thereof together with a pharmaceutically acceptable carrier or excipient.
